Advice
Conditional Marketing Authorisaton withdrawn
On 8 March, 2024, the Conditional Marketing Authorisation for mobocertinib (Exkivity) 40 mg hard capsules was withdrawn see link
Medicine details
- Medicine name:
- mobocertinib (Exkivity)
- SMC ID:
- SMC2516
- Indication:
EXKIVITY as monotherapy is indicated for the treatment of adult patients with epidermal growth factor receptor (EGFR) exon 20 insertion mutation-positive locally advanced or metastatic non-small cell lung cancer (NSCLC), who have received prior platinum-based chemotherapy.
- Pharmaceutical company
- Takeda UK Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Status
- Withdrawn
- Date advice published
- 16 January 2023
Additional notes
On 8 March, 2024, the Conditional Marketing Authorisation for mobocertinib (Exkivity) 40 mg hard capsules was withdrawn see link